Hemogenyx Pharmaceuticals shares rise (again) as it inks agreement to commercialise CAR-T

Hemogenyx Pharmaceuticals PLC shares climbed approximately 11%, contributing to a 755% monthly increase, after announcing a letter of intent with Cellin Technologies to commercialize its HG-CT-1 CAR-T therapy for acute myeloid leukaemia in Estonia. This partnership leverages Estonia's hospital exemption pathway to generate initial revenues and valuable real-world patient data, with Hemogenyx retaining all intellectual property and revenue streams.

Analysis

Hemogenyx Pharmaceuticals (LSE:HEMO) has experienced a significant stock appreciation, with an 11% rise today contributing to a 755% gain over the past month, pushing its valuation over £86 million. The primary catalyst for this momentum is the signing of a letter of intent with Cellin Technologies to commercialize its HG-CT-1 CAR-T therapy in Estonia. This strategic partnership uniquely leverages Estonia's 'hospital exemption pathway,' allowing for the use and potential revenue generation from the advanced therapy before securing full, widespread commercial approval. According to the company's CEO, this arrangement not only creates an early revenue stream but also provides crucial real-world patient data to supplement its ongoing Phase I trial. Under the terms, Hemogenyx retains all intellectual property and future revenues, while Cellin provides the necessary regulatory and operational framework, effectively de-risking a portion of the clinical-to-commercial transition.

Key Decisions for Investors

• Investors should view the agreement as a significant de-risking event that provides an accelerated, albeit limited, path to revenue and crucial data collection, strengthening the investment case for the HG-CT-1 therapy.
• Given the stock's parabolic 755% rise in one month, it would be prudent to be cautious of heightened volatility and the potential for a sharp correction, even with the positive fundamental news.
• Monitor for the conversion of the letter of intent into a definitive agreement and track any reported data from the Estonian program, as these will be critical validation milestones for the therapy's efficacy and the company's strategy.